SCHEMBL15670481

SCHEMBL15670481

COC(=O)C(N)(C(=O)OC(C)(C)C)c1ccc(F)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.40
HDAC6 Q9UBN7 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
DGAT1 O75907 1/20 0.38
ALPL P05186 1/20 0.36
KCNH2 Q12809 1/20 0.35
NR3C2 P08235 2/20 0.35
NPC1 O15118 2/20 0.35
GAA P10253 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898661 0.88 DGAT1 (0.37) DGAT1
SCHEMBL2891442 0.88 DGAT1 (0.37) DGAT1
SCHEMBL16068697 0.78 HDAC6 (0.37) KCNN4HDAC6HDAC3HDAC1HDAC2
SCHEMBL31560826 0.76 HDAC6 (0.43) KCNN4HDAC6HDAC3HDAC1HDAC2
SCHEMBL8780648 0.76 HDAC6 (0.43) KCNN4HDAC6HDAC3HDAC1HDAC2
SCHEMBL5196497 0.76 HDAC1 (0.34) HDAC1HDAC2
SCHEMBL2897024 0.75 DGAT1 (0.38) DGAT1RAB9ACYP3A4
SCHEMBL3178998 0.74 KCNN4 (0.43) KCNN4HDAC6HDAC3HDAC1HDAC2
SCHEMBL27842703 0.74 HDAC3 (0.39) HDAC6HDAC3HDAC1HDAC2CYP1A2
SCHEMBL17041228 0.72 HDAC6 (0.46) KCNN4HDAC6HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2912034-B1 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL HOFFMANN LA ROCHE (CH) 2017-05-31 EP disclosed
US-9611232-B2 Oxazolidinone and imidazolidinone compounds HOFFMANN-LA ROCHE INC. (US) 2017-04-04 US disclosed
US-20150246894-A1 NOVEL OXAZOLIDINONE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2015-09-03 US disclosed
EP-2912034-A1 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL F. Hoffmann-La Roche AG (CH) 2015-09-02 EP disclosed
WO-2014067861-A1 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL F. HOFFMANN-LA ROCHE AG (CH) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246894-A1 NOVEL OXAZOLIDINONE COMPOUNDS OXA1L, CDK11B, CDK11A KCNN4 1834/4885HDAC6 253/4885HDAC3 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.